UA5981A1 - Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі - Google Patents

Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі

Info

Publication number
UA5981A1
UA5981A1 UA3379949A UA3379949A UA5981A1 UA 5981 A1 UA5981 A1 UA 5981A1 UA 3379949 A UA3379949 A UA 3379949A UA 3379949 A UA3379949 A UA 3379949A UA 5981 A1 UA5981 A1 UA 5981A1
Authority
UA
Ukraine
Prior art keywords
phenethylamine
sulfamoyl
preparation
acid salt
substituted derivative
Prior art date
Application number
UA3379949A
Other languages
English (en)
Inventor
Імаї Казуо
Hіїгата Куніхіро
Фудзікура Такасі
Хасімото Сінаті
Такєнака Тоїті
Original Assignee
Ямануті Фармасьютікал Ко., Лтд
Яманути Фармасьютикал Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11859488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA5981(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ямануті Фармасьютікал Ко., Лтд, Яманути Фармасьютикал Ко., Лтд filed Critical Ямануті Фармасьютікал Ко., Лтд
Publication of UA5981A1 publication Critical patent/UA5981A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/10—Radicals substituted by singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
UA3379949A 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі UA5981A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1438280A JPS56110665A (en) 1980-02-08 1980-02-08 Sulfamoyl-substituted phenetylamine derivative and its preparation

Publications (1)

Publication Number Publication Date
UA5981A1 true UA5981A1 (uk) 1994-12-29

Family

ID=11859488

Family Applications (3)

Application Number Title Priority Date Filing Date
UA3379949A UA5981A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі
UA3245545A UA5980A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей
UA3382004A UA5990A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщених похідних фенетіламіна або його солянокислої солі

Family Applications After (2)

Application Number Title Priority Date Filing Date
UA3245545A UA5980A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей
UA3382004A UA5990A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщених похідних фенетіламіна або його солянокислої солі

Country Status (17)

Country Link
US (6) US4373106A (uk)
EP (1) EP0034432B1 (uk)
JP (1) JPS56110665A (uk)
AR (2) AR227533A1 (uk)
AT (1) ATE7223T1 (uk)
AU (1) AU541720B2 (uk)
CA (1) CA1177849A (uk)
DE (2) DE3163257D1 (uk)
ES (1) ES499224A0 (uk)
GR (1) GR73827B (uk)
IE (1) IE50862B1 (uk)
LU (1) LU90000I2 (uk)
MX (2) MX6859E (uk)
NL (1) NL950014I2 (uk)
PT (1) PT72460B (uk)
SU (3) SU1082320A3 (uk)
UA (3) UA5981A1 (uk)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62114952A (ja) * 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JPH066565B2 (ja) * 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
US4971990A (en) * 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same
EP0416804B1 (en) * 1989-09-04 1993-05-26 Yamanouchi Pharmaceutical Co. Ltd. External preparation containing amusulosin
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
WO1995002419A1 (fr) * 1993-07-14 1995-01-26 Yamanouchi Pharmaceutical Co., Ltd. Remede agissant contre le dysfonctionnement urinaire associe a l'hypertrophie de la prostate
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
JP2000509258A (ja) * 1996-04-12 2000-07-25 ベス・イスラエル・デイーコネス・メデイカル・センター・インコーポレーテツド 糖尿病用補足バー
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
EP1075486A1 (en) * 1998-05-06 2001-02-14 Duke University Method of treating bladder and lower urinary tract syndromes
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
CN1163224C (zh) 1998-09-30 2004-08-25 武田药品工业株式会社 改善膀胱排泄能力的药物
KR20020016944A (ko) * 1999-08-09 2002-03-06 오노다 마사요시 하부 요로증 치료용 의약 조성물
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
US6835853B2 (en) 2001-10-31 2004-12-28 Synthon Bv Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
SI1443917T1 (sl) * 2001-11-07 2006-06-30 Synthon Bv Tablete tamsulozina
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
JP2005524693A (ja) 2002-04-24 2005-08-18 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 良性前立腺増殖症の治療又は急性尿閉の長期予防用の医薬組成物
US6894188B1 (en) 2002-04-30 2005-05-17 Ranbaxy Laboratory Limited Tamsulosin derivative
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
WO2004016582A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited An improved process for the preparation of tamsulosin hydrochloride
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ATE430128T1 (de) * 2002-12-26 2009-05-15 Cadila Healthcare Ltd Verfahren zur zubereitung von enantiomerisch reinem (r) oder (s)-5-(2-aminopropyl)-2- methoxybenzensulfonamid
KR100503639B1 (ko) 2003-02-12 2005-07-26 보령제약 주식회사 탐술로신의 정제 방법
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
DE10315702A1 (de) * 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
KR100596373B1 (ko) * 2003-12-09 2006-07-04 씨제이 주식회사 광학적으로 순수한 펜에틸 아민 유도체의 제조방법
SI21655A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska dru�ba d.d. Sinteza optično čistega (R)-5-(2-aminopropil)-2-metoksibenzensulfonamida
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006004093A1 (ja) * 2004-07-07 2006-01-12 Hamari Chemicals, Ltd. 光学活性フェニルプロピルアミン誘導体の製法
CN100545148C (zh) * 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性前列腺肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) * 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
CA2588017A1 (en) * 2004-12-13 2006-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
ES2258394B1 (es) * 2004-12-31 2007-12-01 Quimica Sintetica, S.A. Procedimiento enzimatico para la preparacion de un compuesto intermedio y su uso en la sintesis de tamsulosina clorhidrato.
CA2602198C (en) * 2005-03-21 2010-11-09 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
CA2607809A1 (en) * 2005-05-04 2007-01-11 Medichem, S.A. Process for the preparation of tamsulosin
WO2006134212A2 (en) * 2005-06-15 2006-12-21 Fermion Oy Preparation of tamsulosin hydrochloride from tamsulosi
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007031823A1 (en) * 2005-09-12 2007-03-22 Aurobindo Pharma Limited An improved process for preparing tamsulosin hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
US20080039473A1 (en) * 2006-08-08 2008-02-14 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CA2697137A1 (en) * 2007-07-20 2009-01-29 Astellas Pharma Inc. Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
US20100261770A1 (en) 2007-12-21 2010-10-14 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
PL2394648T3 (pl) 2009-02-04 2016-12-30 Kompozycja farmaceutyczna do podawania doustnego
EP2255793A1 (en) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin
CN102647971B (zh) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
CN102050766B (zh) * 2009-11-03 2013-08-07 安徽省新星药物开发有限责任公司 一种盐酸氨磺洛尔的合成方法
BR112012022073A2 (pt) 2010-03-03 2017-10-31 Boehringer Ingelheim Vetmedica Gmbh uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106478467B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 制备稳定的盐酸坦索罗辛的方法
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701808A (en) * 1967-12-21 1972-10-31 Allen & Hanburys Ltd Phenylethanolamines
BE741762A (uk) * 1968-11-18 1970-05-19
US3878212A (en) * 1970-04-28 1975-04-15 Clemens Rufer Blood sugar lowering sulfamoyl pyrimidines and asymmetrical carbon atom
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
US3711545A (en) * 1971-02-23 1973-01-16 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
US3860647A (en) * 1973-08-20 1975-01-14 Smithkline Corp {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS5553261A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd New phenylethanolamine derivative and its preparation
JPS5553262A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd Phenylethanolamine derivative
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3110573A1 (de) * 1981-03-18 1982-10-21 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n- und o-substituierten di- und/oder polyurethanen
JPS5950671B2 (ja) * 1982-08-26 1984-12-10 山之内製薬株式会社 フェニルエタノ−ルアミン誘導体およびその製造法
US4558106A (en) * 1983-03-29 1985-12-10 Union Carbide Corporation Polymerization process using metal formate to reduce the color of thermoplastic copolymers

Also Published As

Publication number Publication date
JPS6252742B2 (uk) 1987-11-06
JPS56110665A (en) 1981-09-01
UA5980A1 (uk) 1994-12-29
MX6859E (es) 1986-09-08
ES8201966A1 (es) 1982-01-01
US4731478A (en) 1988-03-15
US4868216A (en) 1989-09-19
PT72460A (en) 1981-03-01
MX9203592A (es) 1992-07-31
DE19675042I2 (de) 2001-06-13
SU1181540A3 (ru) 1985-09-23
SU1248533A3 (ru) 1986-07-30
IE50862B1 (en) 1986-08-06
AR227533A1 (es) 1982-11-15
LU90000I2 (fr) 1997-03-04
GR73827B (uk) 1984-05-04
AU6689681A (en) 1981-08-13
CA1177849A (en) 1984-11-13
EP0034432B1 (en) 1984-04-25
SU1082320A3 (ru) 1984-03-23
AU541720B2 (en) 1985-01-17
ATE7223T1 (de) 1984-05-15
ES499224A0 (es) 1982-01-01
US4373106A (en) 1983-02-08
NL950014I1 (nl) 1996-12-02
IE810236L (en) 1981-08-08
EP0034432A2 (en) 1981-08-26
US4987152A (en) 1991-01-22
EP0034432A3 (en) 1982-03-24
US4703063A (en) 1987-10-27
AR230433A1 (es) 1984-04-30
DE3163257D1 (en) 1984-05-30
US4761500A (en) 1988-08-02
PT72460B (en) 1982-02-04
UA5990A1 (uk) 1994-12-29
NL950014I2 (nl) 1997-01-06

Similar Documents

Publication Publication Date Title
UA5981A1 (uk) Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі
AR240949A1 (es) Procedimiento para preparar derivados de acido n-(aminoalcanoil)-aza-biciclocarboxilico
ES490113A0 (es) Metodo de preparacion de aril-3 aminometil-5 oxazolidinonas-2 nuevas
IT1085354B (it) Derivato dell'acido prostanico e procedimento per la sua preparazione
AR225363A1 (es) Procedimiento para la preparacion de acido alfa-hidroxi-gamma-metilmercaptobutirico
PL204747A1 (pl) Sposob wytwarzania kwasu d,1-5-metyloczterowodorofoliowego oraz jego soli
KR860004910A (ko) 5'-메틸티오-5'-데옥시아데노신과 장쇄알킬 설폰산의 염의 제조방법
PT75636B (en) Method for the preparation of 3-phenyl-1-indamines isomers thereof and acid addition salts
IT1131779B (it) Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
JPS52122377A (en) Method of preparation of 22chloronicotinic acid
PL202419A1 (pl) Sposob otrzymywania soli kwasow dwukarbokrylowych i poliamin
ES502653A0 (es) Metodo de preparacion de ftalimidoguanidinas
RO82381A (ro) Procedeu pentru prepararea esterilor acidului 3-acilazopropionic
JPS54111496A (en) Crosssbreeding method of shrimps
PL208386A1 (pl) Sposob wytwarzania halogenkow kwasow alfa-chlorowcoalkilokarbaminowych
RO83054A2 (ro) Procedeu pentru prepararea esterilor acidului monocloracetic
ES555502A0 (es) Metodo de preparacion de carbazatos
MX5738A (es) Derivados de acido ciclohexandioncarboxilico y procedimiento para su preparacion
IT1165251B (it) Metodo di furificazione dell'acido chenodesossicolico
PL205874A1 (pl) Sposob wytwarzania roztworow poliamidow
IT8026359A0 (it) Metodo di preparazione dell'acido 7-(d-alfa-fenilglicilamido)-3-cloro -3-cefem-4-carbossilico
SU1036002A1 (ru) ТЕТРААЛКИЛАММОНИЕВЫЕ СОЛИ ПРОИЗВОДНЫХ п-АМИНО-N-БЕНЗОЛСУЛЬФАМИДА И СПОСОБ ИХ ПОЛУЧЕНИЯ
IT7919880A0 (it) Derivato di acido 2-fenilpropionico e procedimento per la sua preparazione.
PL207343A1 (pl) Sposob otrzymywania kwasu amino-izopropylofosfonowego
AR209701A1 (es) Metodo de preparacion de acidos fenoxi-isoalquilcarboxilicos